CN114591398B - 一种多肽修饰的荧光素衍生物及其制备方法和应用 - Google Patents

一种多肽修饰的荧光素衍生物及其制备方法和应用 Download PDF

Info

Publication number
CN114591398B
CN114591398B CN202210177341.0A CN202210177341A CN114591398B CN 114591398 B CN114591398 B CN 114591398B CN 202210177341 A CN202210177341 A CN 202210177341A CN 114591398 B CN114591398 B CN 114591398B
Authority
CN
China
Prior art keywords
polypeptide
fmoc
fluorescein derivative
reaction
finished
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210177341.0A
Other languages
English (en)
Other versions
CN114591398A (zh
Inventor
温莹
景宁
阴彩霞
霍方俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei Bankpeptide Biological Technology Co ltd
Original Assignee
Shanxi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi University filed Critical Shanxi University
Priority to CN202210177341.0A priority Critical patent/CN114591398B/zh
Publication of CN114591398A publication Critical patent/CN114591398A/zh
Application granted granted Critical
Publication of CN114591398B publication Critical patent/CN114591398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N2021/6417—Spectrofluorimetric devices
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种多肽修饰的荧光素衍生物的合成方法和应用，所述衍生物中文名称为：(Z)‑N6‑(3',6'‑二羟基‑3‑氧代‑3H‑螺环[异苯并呋喃‑1,9'‑黄嘌呤]‑5‑羰基)‑N2‑(4‑((4‑(二甲氨基)苯基)二氮基)苯甲酰基)色氨酸‑异亮氨酸‑苯丙氨酸‑脯氨酸‑色氨酸‑异亮氨酸‑谷氨酰胺‑赖氨酸；该衍生物可特异性检测葡萄糖调节蛋白GRP78。本发明还提供了一种检测GRP78的方法，即将所述衍生物在PBS体系中，通过荧光分光光度计对GRP78进行特异性检测。该检测方法灵敏度高，特异性强，方法简便，操作简单。

Description

一种多肽修饰的荧光素衍生物及其制备方法和应用
技术领域
本发明涉及基于肽链的荧光探针，具体属于一种多肽修饰的荧光素衍生物及其制备方法及其在生物检测中的应用。
背景技术
葡萄糖调节蛋白78(GRP78)在被禽肉瘤病毒感染的纤维原母细胞中发现，其在细胞内的表达量与葡萄糖的供应量呈负相关，并且它的蛋白分子量为78kD，因此被称为葡萄糖调节蛋白78。正常细胞中，GRP78主要存在于内质网中，它的作用是结合新生成的以及折叠出错的多肽，并帮助其正确地折叠和组装。此外，GRP78还是内质网的一种应激感受器。
作为内质网中一种重要的应激蛋白，GRP78会因为肿瘤细胞处于缺氧、缺糖和酸性微环境等因素而在肿瘤细胞中过表达，过量的GRP78可能突破内质网而进入细胞核、线粒体、细胞质以及细胞的分泌物中，进而参与调控胞内信号及影响肿瘤微环境，促进肿瘤的发生发展。化学生物学需要发展新的技术和方法来研究GRP78参与的生物学事件。随着现代合成技术的改进，制备了许多高性能多功能荧光探针，不仅可有效作为生活系统信号通路的视觉荧光追踪，还可作为有效干预生理和病理过程的药物。
对于生命系统中这一重要的应激蛋白，近年来，研究表明，GRP78表达异常可能与许多疾病(如肿瘤疾病)密切相关。进一步研究其生理作用有利于有效的干预以预防相关疾病的发生或发展。
发明内容
本发明的目的在于提供一种多肽修饰的荧光素衍生物及其制备方法，以及将该衍生物用于特异性检测GRP78蛋白。
本发明提供的一种多肽修饰的荧光素衍生物，中文名称为(Z)-N6-(3',6'-二羟基-3-氧代-3H-螺环[异苯并呋喃-1,9'-黄嘌呤]-5-羰基)-N2-(4-((4-(二甲氨基)苯基)二氮基)苯甲酰基)色氨酸-异亮氨酸-苯丙氨酸-脯氨酸-色氨酸-异亮氨酸-谷氨酰胺-赖氨酸；其英文名为(Z)-N6-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carbonyl)-N2-(4-((4-(dimethylamino)phenyl)diazenyl)benzoyl)tryptophy-lisoleucylphenylalanylprolyltryptophylisoleucylglutaminylleucyllysine；结构式如下：
本发明提供的一种多肽修饰的荧光素衍生物的合成方法，步骤如下：
(1)按摩尔比4:5:5将氯甲基树脂、4-二甲胺偶氮苯-4’-羧基-色氨酸(简称Dabcyl-色氨酸-OH，Dabcyl-Trp-OH)、N,N-二异丙基乙胺(简称DIPEA)加入多肽固相反应器，另外加入二氯甲烷作为反应溶液，反应完毕后抽干，用N,N-二甲基甲酰胺(简称DMF)洗涤；
(2)按体积比9～10:1将甲醇和DIPEA加入多肽固相反应器，反应完毕后用DMF洗涤；
(3)按摩尔比1～1.2:1将Fmoc-异亮氨酸(简称Fmoc-ILE-OH)、1-羟基苯并三唑(简称HOBT)加入多肽固相反应器中，DMF做溶剂，滴加催化量的N,N'-二异丙基碳二亚胺(简称DIC)，反应完毕后抽干并用DMF洗涤；
(4)向多肽固相反应器中加入含20％哌啶的DMF溶液(v/v)，反应完毕后抽干并用DMF洗涤；
(5)按照顺序重复步骤(3)、(4)7次，依次将步骤(3)中的Fmoc-异亮氨酸替换为Fmoc-苯丙氨酸、Fmoc-脯氨酸、Fmoc-色氨酸、Fmoc-异亮氨酸、Fmoc-谷氨酰胺、Fmoc-亮氨酸、Fmoc-赖氨酸，反应结束，经甲醇洗涤后抽干；
(6)按体积比95:2:2:1取冷的三氟乙酸(简称TFA)，加入三异丙基硅烷、1,2-乙二硫醇和H2O，配置成冷的95％的三氟乙酸(简称TFA)切割液；
(7)将步骤(6)配置的切割液倒入多肽固相反应器，反应完毕后抽滤，取液体；
(8)加入15～20倍体积的冰乙醚，离心，去上清液，重复洗涤后风干；
(9)液相色谱纯化得到纯品，冷冻干燥机干燥待用，记为peptide；
(10)按摩尔比1:1.2～1.5将5-羧基荧光素和步骤(9)得到的peptide用磷酸缓冲盐溶液溶解，反应4h，质谱检测，HPLC纯化，冻干得到成品即为多肽修饰的荧光素衍生物。
上述制备的荧光素衍生物，包含2部分组成：5-羧基荧光素作为荧光团和由猝灭基Dabcyl修饰的多肽链。此多肽链能够特异性与GRP78蛋白结合。当上述制备的荧光素衍生物与GRP78特异性结合时，多肽链构象发生变化，影响荧光团与猝灭基之间的空间距离。因此，上述制备的荧光素衍生物能够实现GRP78蛋白的特异性检测。
本发明提供的一种特异性检测GRP78蛋白的检测方法，步骤为：
(1)配制pH7.4的磷酸缓冲盐溶液(10mM)，将荧光素衍生物溶于二甲基亚砜(DMSO)配制成1mM的储备液，配制250mg/L的GRP78水溶液；
(2)紫外-可见光谱：取975μL磷酸缓冲盐溶液、5μL荧光素衍生物储备液、20μLGRP78水溶液，置于比色皿中，进行紫外扫描；取995μL的磷酸缓冲盐溶液、5μL荧光素衍生物储备液，置于比色皿中，进行紫外扫描；
(3)荧光光谱：取975μL磷酸缓冲盐溶液、5μL荧光素衍生物储备液、20μLGRP78水溶液，置于比色皿中，以490nm作为激发波长，每隔为10min，进行荧光光谱扫描；取995μL磷酸缓冲盐溶液、5μL荧光素衍生物储备液，置于比色皿中，以490nm作为激发波长，进行荧光光谱扫描；
(4)工作曲线：取5个2mL的EP管中，在每个EP管中分别加入990μL磷酸缓冲盐溶液和5μL荧光素衍生物储备液；然后依次在5个EP管中分别加入不同量的GRP78水溶液，使GRP78的终浓度分别为0.2μg/mL，0.4μg/mL，0.6μg/mL，0.8μg/mL，1.0μg/mL；摇匀放置2小时后，以490nm为激发波长，进行荧光扫描，得样品在530nm处的荧光强度；以GRP78浓度为横坐标，以530nm处荧光强度值为纵坐标绘制图，并做线性分析。
与现有技术相比，本发明具有如下优点和效果：
1、本发明多肽修饰的荧光素衍生物可用于特异性检测GRP78蛋白；
2、本发明技术操作简单，检测简便，仅需紫外分光光度计和荧光光谱仪；
3、本发明荧光素衍生物用于特异性检测GRP78，检测信号明显，反应时间迅速。
附图说明
图1实施例1制备的荧光素衍生物的质谱图
图2实施例1制备的荧光素衍生物的色谱图
图3实施例2荧光素衍生物与GRP78反应的紫外光谱图
图4实施例3荧光素衍生物与GRP78反应的荧光光谱图
图5实施例4荧光素衍生物与GRP78在530nm处荧光强度的线性关系图
图6实施例5荧光素衍生物在530nm处的选择性柱状图
图7实施例6荧光素衍生物孵育细胞不同时间后的细胞成像图
图8实施例6荧光素衍生物孵育细胞不同时间后的荧光强度图
图9实施例7荧光素衍生物对小鼠瘤内注射不同时间后的活体成像图
图10实施例7荧光素衍生物对小鼠瘤内注射180min后进行解剖的脏器及肿瘤成像图
具体实施方式
下面结合实施例和附图对本发明做进一步说明，但本发明不受下述实施例的限制。
实施例1
本发明多肽修饰的荧光素衍生物的合成和表征：
(1)称取1.0g氯甲基树脂(取代度：0.4mmol/g)加入多肽固相反应器，二氯甲烷浸泡10min，加入226.2mg的Dabcyl-色氨酸(简称Dabcyl-Lys-OH，0.48mmol)、79.3mL的N,N-二异丙基乙胺(简称DIPEA，0.48mmol)，反应2h，抽干，用N,N-二甲基甲酰胺(简称DMF)洗涤4次；
(2)加入甲醇180mL，DIPEA 20mL，反应30min，DMF洗涤4次；
(3)称取445.7mg的Fmoc-异亮氨酸(简称Fmoc-ILE-OH，1.2mmol)、162.1mg的1-羟基苯并三唑(简称HOBT，1.2mmol)加入反应器中，DMF做溶剂，滴加0.2mL的N,N'-二异丙基碳二亚胺(简称DIC)，反应1h，抽干，DMF洗涤4次；
(4)向反应器中加入20％的哌啶DMF溶液(v/v)反应20min，抽干，DMF洗涤6次；
(5)按照顺序重复步骤(3)、(4)7次，依次将步骤(3)中的Fmoc-异亮氨酸替换为Fmoc-苯丙氨酸、Fmoc-脯氨酸、Fmoc-色氨酸、Fmoc-异亮氨酸、Fmoc-谷氨酰胺、Fmoc-亮氨酸、Fmoc-赖氨酸，反应结束，经甲醇洗涤4次后抽干；
(6)配置冷的95％的三氟乙酸(简称TFA)切割液：取95mL冷的TFA，加入2mL三异丙基硅烷、2mL 1,2-乙二硫醇和1mLH2O。
(7)将(6)配置的切割液倒入反应器，反应2h，抽滤，取液体。
(8)加入15倍体积的冰乙醚，离心，去上清液，重复洗涤3次后，风干。
(9)液相色谱纯化得到纯品，冷冻干燥机干燥待用，记为peptide。
(10)称取37.6mg的5-羧基荧光素(0.1mmol)、177.7mg的peptide(0.12mmol)，用磷酸缓冲盐溶液溶解，反应4h，质谱检测，HPLC纯化，冻干得到成品为多肽修饰的荧光素衍生物。
对上述制备的多肽修饰的荧光素衍生物进行表征：
该衍生物的质谱图见图1，该图显示出了荧光素衍生物的分子量正确。ESI-MS m/z:calc.for C101H116N16O18 +[M+2H]2+920.4327,found 920.4314。
该衍生物的高效液相色谱图见图2，该图显示了制备的荧光素衍生物的纯度大于95％。
实施例2
紫外-可见吸收光谱：取975μL的pH7.4的10mM的磷酸缓冲盐溶液、5μL的1mM的荧光素衍生物储备液、20μL中的250mg/L的GRP78水溶液，置于比色皿中，进行紫外扫描；取的pH7.4的10mM的磷酸缓冲盐溶液、5μL的中的1mM的荧光素衍生物储备液，置于比色皿中，进行紫外扫描。光谱性质显示：与不含有GRP78的荧光素衍生物溶液的紫外-可见吸收光谱相比，含有GRP78的荧光素衍生物的溶液的在490nm处的吸收值有所增加。结果如图3所示。
实施例3
荧光光谱：取975μL的pH 7.4的10mM的磷酸缓冲盐溶液、5μL的1mM的荧光素衍生物储备液、20μL中的250mg/L的GRP78水溶液，加到比色皿中，以490nm波长激发对上述混合溶液进行荧光扫描，时间间隔为10min；取995μL的pH 7.4的10mM的磷酸缓冲盐溶液、5μL的1mM的荧光素衍生物储备液，加到比色皿中，以490nm波长激发对荧光素衍生物进行荧光扫描。结果如图4所示。荧光光谱显示：以490nm为激发，GRP78的额外加入使得荧光素衍生物在530nm处的荧光强度随着时间的增加而增强。
实施例4
工作曲线：取5个2mL的EP管中，在每个EP管中分别加入990μL的pH 7.4的10mM的磷酸缓冲盐溶液；5μL的1mM的荧光素衍生物储备液。然后依次在5个EP管中分别加入不同量的GRP78水溶液，使GRP78的终浓度分别为0.2μg/mL，0.4μg/mL，0.6μg/mL，0.8μg/mL，1.0μg/mL；摇匀放置2小时后，以490nm为激发波长，进行荧光扫描，得样品在530nm处的荧光强度；以GRP78浓度为横坐标，以530nm处荧光强度值为纵坐标绘制图，并做线性分析，得线性回归方程为：y＝97.75x+539.19，R2＝0.99346，x的单位为μg/mL。线性关系如图5所示。
实施例5
选择性实验：取5个2mL的EP管中，在每个EP管中分别加入975μL的pH 7.4的10mM的磷酸缓冲盐溶液和5μL的1mM的荧光素衍生物储备液。然后依次在10个EP管中分别加入不同的氨基酸以及其他可能干扰检测的物质。序号及名称分别为1：对照，不额外加入其他氨基酸；2：GRP78蛋白；3：半胱氨酸；4：谷胱甘肽；5：同型半胱氨酸；6：谷胱甘肽巯基转移酶；7：人白蛋白；8：溶菌酶；9：H2O2；10：铁蛋白。2小时后，以490nm作为激发对样品进行荧光扫描。取530nm处的荧光强度值作纵坐标。图6显示：只有加入GRP78才能使得荧光素衍生物在530nm处的荧光强度值增加。
实施例6
细胞成像实验：取10μL步骤(1)中的荧光素衍生物储备液加入到2mL的细胞培养液中，使得其浓度为10μM；在37℃下分别用上述溶液孵育人结肠癌细胞HCT116和人肝正常细胞HL7702一定的时间，包括20min、40min、60min、120min，用2mL磷酸缓冲盐溶液洗涤细胞3次。在激光扫描共聚焦显微镜下成像。激发波长为488nm，荧光信号收集波长为500-560nm。所有实验组结果如图7所示，随着探针孵育时间的增长，HCT116细胞上搜集到的荧光信号逐渐增强，而HL7702细胞上搜集到的荧光信号无明显变化，对其进行定量处理得图8。
实施例7
肿瘤成像实验：对皮下接种HCT116细胞的荷瘤小鼠进行瘤内注射步骤1mM的荧光素衍生物储备液20μL。用小动物成像仪成像小鼠肿瘤处的荧光信号变化。实验结果如图9所示，注射后，其荧光信号随着时间的增加而增加；对小鼠进行解剖并取肿瘤和主要脏器进行成像，实验结果如图10所示，肿瘤具有较强的荧光信号而其他脏器无荧光信号，自上而下依次为肝脏、心脏、脾脏、肿瘤、肺脏和肾脏。

Claims (7)

1.一种多肽修饰的荧光素衍生物，其特征在于，结构式如下：
2.如权利要求1所述的一种多肽修饰的荧光素衍生物的合成方法，其特征在于，步骤如下：
(1)按摩尔比4:5:5将氯甲基树脂、4-二甲胺偶氮苯-4’-羧基-色氨酸、N,N-二异丙基乙胺(DIPEA)加入多肽固相反应器，另外加入二氯甲烷作为反应溶液，反应完毕后抽干，用N,N-二甲基甲酰胺(DMF)洗涤；
(2)按体积比9～10:1将甲醇和DIPEA加入多肽固相反应器，反应完毕后用DMF洗涤；
(3)按摩尔比1～1.2:1将Fmoc-异亮氨酸、1-羟基苯并三唑加入多肽固相反应器中，DMF做溶剂，滴加催化量的N,N'-二异丙基碳二亚胺，反应完毕后抽干并用DMF洗涤；
(4)向多肽固相反应器中加入含20％哌啶的DMF溶液，反应完毕后抽干并用DMF洗涤；
(5)按照顺序重复步骤(3)、(4)7次，依次将步骤(3)中的Fmoc-异亮氨酸替换为Fmoc-苯丙氨酸、Fmoc-脯氨酸、Fmoc-色氨酸、Fmoc-异亮氨酸、Fmoc-谷氨酰胺、Fmoc-亮氨酸、Fmoc-赖氨酸，反应结束，经甲醇洗涤后抽干；
(6)按体积比95:2:2:1取冷的三氟乙酸(TFA)，加入三异丙基硅烷、1,2-乙二硫醇和H2O，配置成冷的95％的TFA切割液；
(7)将步骤(6)配置的切割液倒入多肽固相反应器，反应完毕后抽滤，取液体；
(8)加入15～20倍体积的冰乙醚，离心，去上清液，重复洗涤后风干；
(9)液相色谱纯化得到纯品，冷冻干燥机干燥待用，记为peptide；
(10)按摩尔比1:1.2～1.5将5-羧基荧光素和步骤(9)得到的peptide用磷酸缓冲盐溶液溶解，反应4h，质谱检测，HPLC纯化，冻干得到成品即为多肽修饰的荧光素衍生物。
3.如权利要求2所述的多肽修饰的荧光素衍生物的合成方法，其特征在于，所述步骤(2)中甲醇和DIPEA的体积比为9:1。
4.如权利要求2所述的多肽修饰的荧光素衍生物的合成方法，其特征在于，所述步骤(3)中Fmoc-异亮氨酸和1-羟基苯并三唑的摩尔比为1:1。
5.如权利要求2所述的多肽修饰的荧光素衍生物的合成方法，其特征在于，所述步骤(10)中5-羧基荧光素和peptide的摩尔比为1:1.2。
6.如权利要求1所述的多肽修饰的荧光素衍生物在制备检测GRP78探针中的应用。
7.如权利要求1所述的多肽修饰的荧光素衍生物在制备细胞成像探针中的应用。
CN202210177341.0A 2022-02-24 2022-02-24 一种多肽修饰的荧光素衍生物及其制备方法和应用 Active CN114591398B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210177341.0A CN114591398B (zh) 2022-02-24 2022-02-24 一种多肽修饰的荧光素衍生物及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210177341.0A CN114591398B (zh) 2022-02-24 2022-02-24 一种多肽修饰的荧光素衍生物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114591398A CN114591398A (zh) 2022-06-07
CN114591398B true CN114591398B (zh) 2023-09-22

Family

ID=81804485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210177341.0A Active CN114591398B (zh) 2022-02-24 2022-02-24 一种多肽修饰的荧光素衍生物及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN114591398B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195240A1 (en) * 2014-06-09 2015-12-23 University Of Iowa Research Foundation Grp78 targeted conjugates
CN105199000A (zh) * 2015-10-29 2015-12-30 山西大学 一种靶向抗肿瘤活性蛋白及其制备与纯化
CN107201397A (zh) * 2016-05-09 2017-09-26 上海市同济医院 一种用于检测人源性grp78基因表达水平的引物组合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195240A1 (en) * 2014-06-09 2015-12-23 University Of Iowa Research Foundation Grp78 targeted conjugates
CN105199000A (zh) * 2015-10-29 2015-12-30 山西大学 一种靶向抗肿瘤活性蛋白及其制备与纯化
CN107201397A (zh) * 2016-05-09 2017-09-26 上海市同济医院 一种用于检测人源性grp78基因表达水平的引物组合物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Haiwei Ji.Lightening up Intracelluar Prognostic Indicator in Early-Stage Cancer.ChemComm.2015,第51卷(第8期),1479-82. *
Lichao Zhang.Design, purification and assessment of GRP78 binding peptide-linked Subunit A of Subtilase cytotoxic for targeting cancer cells.BMC Biotechnology.2016,第16卷(第65期),1-13. *
温莹.酯酶荧光探针的研究现状与进展.大学化学.2021,第37卷(第3期),2110036. *

Also Published As

Publication number Publication date
CN114591398A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
CN100425612C (zh) 一种检测过氧化氢的荧光探针及其合成方法和用途
CN109970751B (zh) 一种双位点、高灵敏pH荧光探针及其合成与应用
CN108117544A (zh) 一种可逆二氧化硫/亚硫酸（氢）盐的荧光探针
CN112266351B (zh) 一种双光子比率荧光探针及其制备方法与应用
CN111253356A (zh) 一种香豆素-苯并吡喃鎓盐衍生物及其合成方法和应用
CN110041311B (zh) 一种荧光探针分子ml-fp及其制备方法和应用
Wang et al. A “turn-on” near-infrared fluorescent probe with high sensitivity for detecting reduced glutathione based on red shift in vitro and in vivo
CN114591398B (zh) 一种多肽修饰的荧光素衍生物及其制备方法和应用
Miloslavina et al. An unusual peptide from Conus villepinii: synthesis, solution structure, and cardioactivity
CN106478505A (zh) 一种双光子gsh探针及其制备与应用
CN110452236B (zh) 一种香豆素类半胱氨酸荧光探针及其制备方法与应用
CN110655510B (zh) 一种靶向脂滴的亚硫酸盐比率荧光探针及其应用
CN108148056B (zh) 比率型近红外半胱氨酸荧光探针
CN108191848B (zh) 制备用于检测半胱氨酸的试剂盒的方法
CN108148057B (zh) 制备用于检测半胱氨酸的荧光探针的方法
CN110862384A (zh) 一种吲哚荧光探针及其制备方法和应用
CN110804087A (zh) 一种整合素αvβ3靶向的AIE荧光化合物及其制备与应用
CN110257055A (zh) 高选择性检测谷胱甘肽比率型荧光探针及合成方法与应用
CN113150575B (zh) 一种近红外的萘酰亚胺染料及其制备方法与应用
CN106496156A (zh) 共轭苯并噻唑衍生物、近红外荧光探针及其制备与应用
CN108362671B (zh) 检测半胱氨酸的方法
CN111303865B (zh) 荧光探针化合物及其制备方法和应用
CN109134545B (zh) 一种线粒体靶向荧光探针及其制备方法与应用
JP4965963B2 (ja) 蛍光性化合物及びタンパク質のトポロジー解析方法
CN115894427B (zh) 近红外频率上转换荧光探针及其制备方法和在检测生物硫醇中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240224

Address after: Floor 4, C6 #, Science and Technology Industrial Park, No. 168 Xiangzhang Avenue, High tech Zone, Hefei City, Anhui Province, 230031

Patentee after: HEFEI BANKPEPTIDE BIOLOGICAL TECHNOLOGY CO.,LTD.

Country or region after: China

Address before: 030006, No. 92, Hollywood Road, Xiaodian District, Shanxi, Taiyuan

Patentee before: SHANXI University

Country or region before: China

TR01 Transfer of patent right